文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.

作者信息

Jafarzadeh Leila, Masoumi Elham, Fallah-Mehrjardi Keyvan, Mirzaei Hamid Reza, Hadjati Jamshid

机构信息

Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Department of Medical Immunology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.

出版信息

Front Immunol. 2020 Apr 22;11:702. doi: 10.3389/fimmu.2020.00702. eCollection 2020.


DOI:10.3389/fimmu.2020.00702
PMID:32391013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7188834/
Abstract

CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments. CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/7495479f6b54/fimmu-11-00702-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/23ac94f26fb3/fimmu-11-00702-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/9c45cd6b41ac/fimmu-11-00702-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/7495479f6b54/fimmu-11-00702-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/23ac94f26fb3/fimmu-11-00702-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/9c45cd6b41ac/fimmu-11-00702-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f0e/7188834/7495479f6b54/fimmu-11-00702-g0003.jpg

相似文献

[1]
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.

Front Immunol. 2020-4-22

[2]
Engineering CAR-T Cells for Next-Generation Cancer Therapy.

Cancer Cell. 2020-10-12

[3]
Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.

Immunotherapy. 2018-3

[4]
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.

Mamm Genome. 2018-7-9

[5]
CAR T Cell Therapy for Solid Tumors.

Annu Rev Med. 2016-11-17

[6]
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

Hepatobiliary Pancreat Dis Int. 2018-5-24

[7]
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.

Front Immunol. 2019-2-5

[8]
Gene modification strategies for next-generation CAR T cells against solid cancers.

J Hematol Oncol. 2020-5-18

[9]
Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.

Cells. 2020-12-24

[10]
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.

Front Immunol. 2018-7-31

引用本文的文献

[1]
Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma.

Mol Ther Nucleic Acids. 2025-8-11

[2]
Unconventional Immunotherapies in Cancer: Opportunities and Challenges.

Pharmaceuticals (Basel). 2025-8-4

[3]
Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.

Int J Hematol Oncol Stem Cell Res. 2025-4-1

[4]
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.

Curr Issues Mol Biol. 2025-4-10

[5]
functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma.

Front Immunol. 2025-1-13

[6]
Engineering resilient CAR T cells for immunosuppressive environment.

Mol Ther. 2025-6-4

[7]
Engineered T cells for Colorectal Cancer.

Immunotherapy. 2024

[8]
EphA3 CAR T cells are effective against glioblastoma in preclinical models.

J Immunother Cancer. 2024-8-7

[9]
Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.

Vaccines (Basel). 2024-6-12

[10]
In silico study of heterogeneous tumour-derived organoid response to CAR T-cell therapy.

Sci Rep. 2024-5-29

本文引用的文献

[1]
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.

Nat Commun. 2020-1-15

[2]
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Mol Ther Oncolytics. 2019-8-28

[3]
An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.

Front Immunol. 2019-7-19

[4]
NR4A transcription factors limit CAR T cell function in solid tumours.

Nature. 2019-2-27

[5]
Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.

Cancer Lett. 2018-6-27

[6]
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Mol Ther. 2018-6-15

[7]
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

Oncoimmunology. 2018-3-15

[8]
Improved Expansion and Function of Patient T Cells by a Serum-free Medium.

Mol Ther Methods Clin Dev. 2017-11-7

[9]
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.

Nat Biotechnol. 2018-3-5

[10]
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.

Leukemia. 2018-2-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索